last year, while gross profit margin was slightly strengthened from 6.83% in 1H/2016 to 7.89% in 1H/2017. Other income in 1H/2017 amounted to Baht 741.35 million, a surge by Baht 375.49 million or 102.63
, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th 2. Costs of sales and gross profit Costs of sales were Baht 117 .60 million in the first nine months of 2019, a surge of Baht 32 .42 million
related corporate tax transaction, the normalized net profit would be approximately THB 97.42 million or a surge of 48% yoy. Page 3 of 4 Statement of Financial Position as of March 31, 2019 The consolidated
March 2018 increased by 19% yoy mainly from the surge of provisions for employee benefit and other liabilities. Most of the increase of other liabilities was income tax payable on 2017 profit because
device sales to decline significantly. The main cause for the decline is the surge in IT devices demand during the COVID-19. Consumers had purchased a large number of IT products such as laptops, tablets
securities business is lost or destroyed, the association related to securities business may submit an application for a substitute of the license. Clause 6 A license for establishment shall take effect on its
profit 34,312 47% 20,859 50% Sales from Producing and distributing electronics spare parts Revenue from sales increased from year 2019, because of increased in diode order from USA to substitute products
distribution in other potential countries of Africa, Americas, and APAC. For domestic market, substitute products from importers got flooded as strong Thai Baht made overall imports cheaper causing intense price
) Gross profit 18,270 49% 6,412 53% Sales from Producing and distributing electronics spare parts Revenue from sales increased from year 2019, because of increased in diodes order from USA to substitute